OM:SINCH
OM:SINCHSoftware

Sinch (OM:SINCH): Losses Accelerate 46% Per Year, Valuation Discount Highlights Profit Turnaround Hopes

Sinch (OM:SINCH) continues to face unprofitability, with losses increasing at an annual rate of 46% over the past five years and no improvement in margins. Yet, the company stands out for its upside potential, as consensus forecasts call for earnings to grow at 70.11% per year, with profitability anticipated within three years. This pace is seen as well above market averages. Investors are weighing these rapid projected profit gains against Sinch’s current discounted share price, which trades...
OM:KARNEL B
OM:KARNEL BIndustrials

Karnell Group (OM:KARNEL B) Profit Margin Surges, Reinforcing Bullish Sentiment This Earnings Season

Karnell Group (OM:KARNEL B) posted a net profit margin of 8.2%, up sharply from last year’s 4.5%. The company’s earnings have climbed at an average rate of 36.9% per year over the past five years, with a recent standout growth of 129.6% in the latest period. This surge in profit growth and enhanced margins, coupled with high quality earnings, puts Karnell Group in the spotlight this earnings season as investors weigh how sustainable these trends might be. See our full analysis for Karnell...
OM:DVYSR
OM:DVYSRBiotechs

Devyser Diagnostics (OM:DVYSR): Five-Year Losses Worsen, But 31% Annual Revenue Growth Sets Up Earnings Season

Devyser Diagnostics (OM:DVYSR) remains unprofitable, with losses deepening at an annual rate of 16.9% over the past five years. However, revenue is forecast to surge by 31.1% per year, outpacing the Swedish market’s 3.7% per year projected growth, and earnings are expected to rise sharply by 119.62% per year with profitability anticipated within the next three years. With the share price trading at SEK 115, well below the estimated fair value of SEK 583.07, investors are likely to focus on...
OM:ONCO
OM:ONCOBiotechs

Oncopeptides (OM:ONCO): Losses Narrow 43% Annually, Growth Outlook Sharpens Valuation Debate

Oncopeptides (OM:ONCO) remains unprofitable, but has aggressively narrowed its losses by 43.3% per year over the past five years. With earnings expected to surge by 95.25% each year and profitability projected within the next three years, investors have plenty to weigh against near-term risks as the company targets annual revenue growth of 71.2%, far outpacing the wider Swedish market. See our full analysis for Oncopeptides. The next step is to see how these figures compare with the broader...
OM:ORRON
OM:ORRONRenewable Energy

Orrön Energy (OM:ORRON): Losses Mount at 57% Annual Rate as 19% Revenue Growth Confronts Market Doubts

Orrön Energy (OM:ORRON) remains in the red, with losses compounding at an average annual rate of 57.4% over the last five years and profit margins still under pressure. While profitability is not expected in the next three years, revenue is forecast to surge at 19.15% per year, outpacing the Swedish market’s 3.7% average. Investors are left weighing Orrön’s premium valuation and strong revenue growth outlook in comparison to a track record of persistent losses and little evidence that a...
OM:CLA B
OM:CLA BFood

Cloetta (OM:CLA B) Profit Margin Surges to 8.3%, Reinforcing Value Narrative

Cloetta (OM:CLA B) delivered standout earnings results this year, with EPS jumping 56.7% compared to its historical average of 14.3% annual growth over the past five years. Net profit margin rose to 8.3%, outpacing last year's 5.4%. However, revenue growth projections of 1.6% per year lag the broader Swedish market's 3.7%. Investors will note that while the company's valuation looks appealing versus industry peers, forecasts now expect earnings to decline by 1.8% per year over the next three...
OM:STOR B
OM:STOR BIndustrials

Storskogen Group (OM:STOR B) Profitability Boosted by One-Off Gain, Raising Questions on Earnings Quality

Storskogen Group (OM:STOR B) just turned profitable, with its net profit margin moving into positive territory for the past year. The company’s earnings include a one-off gain of SEK910.0 million in the latest 12 months ending September 30, 2025, which clouds the picture of underlying profit quality. Over the past five years, earnings have declined by 10.2% per year, and with revenue expected to grow at just 2.9% per year, which is slower than both the broader Swedish market and sector peers,...